TGFBR1 and idiopathic pulmonary fibrosis: Our study provides clear evidence of reproducible therapeutic efficacy of a standard TGFβR1/ALK5i in BLEO‐IPF mice, establishing ALK5i as a reliable reference drug in treatment intervention studies in the model.